drugset / Trial / NCT00759200
Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of alb-interferon in adults with genotype 2 or 3 chronic hepatitis
Timeline
- Start
- 2008-10
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albinterferon Alfa-2b | Protein / enzyme biologic | 900 ug | — |
| Subject | Albinterferon Alfa-2b | Protein / enzyme biologic | 1200 ug | — |
| Subject | Albinterferon Alfa-2b | Protein / enzyme biologic | 1500 ug | — |
| Subject | Albinterferon Alfa-2b | Protein / enzyme biologic | 1800 ug | — |
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | — |